ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane‐based chemotherapy

Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance

(2014) Oliver Bruhn et al.   Expert Opinion on Drug Metabolism & Toxicology

Effects of genetic polymorphisms of OPRM1, ABCB1, CYP3A4/5 on postoperative fentanyl consumption in Korean gynecologic patients

(2013) Kye-Min Kim et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy

(2012) Kyu-pyo Kim et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: A Korean population-based study

(2009) Hee Seung Kim et al.   GYNECOLOGIC ONCOLOGY

Clinical significance of ABCB1 genotyping in oncology

(2009) Alma Hamidovic et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Association of the ABCB1 gene polymorphisms 2677G>T/A and 3435C>T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients

(2008) H. Chang et al.   ANNALS OF ONCOLOGY

Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer

(2008) Henrik Gréen et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel

(2008) T. M. Sissung et al.   CLINICAL CANCER RESEARCH